The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

One of the key characteristics is that unlike antibody-based HER2 drugs like Herceptin and Roche’s Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) it crosses the blood brain barrier, so ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Come Friday, it will be two years since Julie Zimmer rang the bell at the Mercy Health Springfield Cancer Center to celebrate ...

The Best of ASCO UAE Conference 2025, organised by SEHA, part of PureHealth Group, in collaboration with Tawam Hospital, ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.